Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Axonics Inc (NQ: AXNX )

49.31 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Axonics Inc

< Previous 1 2 3 Next >
Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2023
 
Via Benzinga
Where Axonics Stands With Analysts
 
Via Benzinga
Axonics Q1 Soars Past Estimates: Analysts Say Annual Sales Outlook Is 'Conservative'
Axonics Inc (NASDAQ: AXNX) reported a Q1 EPS loss of $(0.19), better than the consensus of $(0.29). 
Via Benzinga
Analyst Ratings for Axonics
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2023
 
Via Benzinga
Earnings Scheduled For March 1, 2023
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million. 
Via Benzinga
Axonics Modulation Tech Earnings Preview
 
Via Benzinga
Analyst Ratings for Axonics
 
Via Benzinga
2 Fast-Growing Healthcare Stocks to Buy and Hold
The innovative companies have made great gains in a short period of time. 
Via The Motley Fool
Earnings Scheduled For May 1, 2023
Companies Reporting Before The Bell • TG Therapeutics (NASDAQ:TGTX) is estimated to report quarterly loss at $0.37 per share on revenue of $3.38 million. 
Via Benzinga
Axonics Earnings Preview
 
Via Benzinga
Axonics Posts Smaller Than Expected Quarterly Loss, Raises Guidance
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 24, 2023
 
Via Benzinga
Why Axonics Shares Are Trading Higher Today?
Axonics, Inc. (NASDAQ: AXNX) shares are trading higher after the company reported preliminary fourth-quarter and full-year 2022 total net revenue results above estimates. The company also issued FY23... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 10, 2022
Upgrades 
Via Benzinga
Where Axonics Stands With Analysts
Within the last quarter, Axonics (NASDAQ:AXNX) has observed the following analyst ratings: 
Via Benzinga
What 9 Analyst Ratings Have To Say About Axonics
Within the last quarter, Axonics (NASDAQ:AXNX) has observed the following analyst ratings: 
Via Benzinga
Analyst Ratings for Axonics
Within the last quarter, Axonics (NASDAQ:AXNX) has observed the following analyst ratings: 
Via Benzinga
Earnings Scheduled For October 31, 2022
Companies Reporting Before The Bell • Insperity (NYSE:NSP) is estimated to report quarterly earnings at $0.96 per share on revenue of $1.46 billion. 
Via Benzinga
Analyst Ratings for Axonics
Axonics (NASDAQ:AXNX) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Axonics Risk/Reward Ratio Is Less Favorable, Analyst Says While Downgrading Stock
Needham downgraded Axonics Inc (NASDAQ: AXNX) from Buy to Hold. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 21, 2022
Upgrades 
Via Benzinga
Leading Medical Stocks, Including Sensus And Shockwave, Have Grown At Least 36% This Year
Biotech isn't the only place to make money in health care this year. 
Via Investor's Business Daily
Piper Sandler Maintains Overweight Rating for Axonics: Here's What You Need To Know
Piper Sandler has decided to maintain its Overweight rating of Axonics (NASDAQ:AXNX) and raise its price target from $82.00 to $84.00. Shares of Axonics are trading down 1.5% over the last 24 hours, at... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2022
Upgrades 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Applied DNA Sciences (NASDAQ:APDN) stock rose 90.0% to $5.32 during Tuesday's after-market session. At the close, Applied DNA Sciences's trading volume reached 28.8 million shares. This is... 
Via Benzinga
Neuromodulation Focused Company Axonics Gets 28% Price Target Bump By This Analyst On Solid Q2 Performance
 
Via Benzinga
Morgan Stanley Maintains Overweight Rating for Axonics: Here's What You Need To Know
Morgan Stanley has decided to maintain its Overweight rating of Axonics (NASDAQ:AXNX) and raise its price target from $73.00 to $80.00. Shares of Axonics are trading up 5.7% over the last 24 hours, at... 
Via Benzinga
Recap: Axonics Q2 Earnings
Axonics (NASDAQ:AXNX) reported its Q2 earnings results on Monday, August 1, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings Axonics beat estimated earnings by... 
Via Benzinga
Earnings Scheduled For August 1, 2022
Companies Reporting Before The Bell • Bon Natural Life (NASDAQ:BON) is projected to report earnings for its first quarter. 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.